• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Tempus AI Inc.

    8/27/25 5:11:01 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology
    Get the next $TEM alert in real time by email
    8-K
    false 0001717115 0001717115 2025-08-27 2025-08-27
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 27, 2025

     

     

    Tempus AI, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Nevada   001-42130   47-4903308
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (I.R.S. Employer
    Identification No.)

    600 West Chicago Avenue, Suite 510

    Chicago, Illinois 60654

    (Address of principal executive offices) (Zip Code)

    800 976-5448

    (Registrant’s telephone number, including area code)

    Not applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Class A common stock, $0.0001 par value per share   TEM   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 8.01

    Other Events.

    On August 8, 2025, Tempus AI, Inc. (the “Company”) filed with the U.S. Securities and Exchange Commission (the “SEC”) an automatic shelf registration statement on Form S-3 (File No. 333-289398). On August 27, 2025, the Company filed with the SEC a prospectus supplement (the “Prospectus Supplement”) covering the resale of up to 1,268,033 shares of the Company’s Class A common stock, par value $0.0001 per share (“Class A common stock”), by the selling stockholders referenced in the Prospectus Supplement. The Company is filing this Current Report on Form 8-K to provide the legal opinion of its counsel, Brownstein Hyatt Farber Schreck, LLP, regarding the legality of the Class A common stock covered by the Prospectus Supplement, which opinion is attached here to as Exhibit 5.1.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits:

     

      

     

    Exhibit

    Number

        

    Description

        5.1      Opinion of Brownstein Hyatt Farber Schreck, LLP.
        23.1      Consent of Brownstein Hyatt Farber Schreck, LLP (included in Exhibit 5.1).
        104      Cover Page Interactive Data File - The cover page from this Current Report on Form 8-K is formatted in Inline XBRL.

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: August 27, 2025

     

    Tempus AI, Inc.
    By:   /s/ James Rogers
      Name:   James Rogers
      Title:   Chief Financial Officer
    Get the next $TEM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TEM

    DatePrice TargetRatingAnalyst
    9/2/2025$90.00Buy
    H.C. Wainwright
    4/21/2025$60.00Buy
    BTIG Research
    2/25/2025$50.00 → $55.00Overweight → Neutral
    Analyst
    2/12/2025Outperform → Mkt Perform
    William Blair
    2/5/2025$58.00 → $74.00Buy
    TD Cowen
    12/13/2024$60.00Outperform
    Wolfe Research
    12/9/2024$74.00Buy
    Guggenheim
    11/11/2024$45.00 → $65.00Buy → Hold
    Stifel
    More analyst ratings

    $TEM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tempus Ai, Inc. exercised 9,218,800 in-the-money shares at a strike of $2.00 and bought $17,745,000 worth of shares (3,500,000 units at $5.07) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Reporting)

    8/20/24 4:17:55 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RNA-based Tempus xR IVD device. xR IVD will be offered as a life sciences tool to support drug development programs. RNA sequencing captures a large array of biological information and offers deeper insights into the mechanisms of diseases, including enhanced fusion detection. RNA analysis is increasingly an important tool in research and development because it can identify molecular pathways and networks that are directly involved in disease progression. "We

    9/22/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

    MarketNewsUpdates News Commentary NEW YORK, Sept. 18, 2025 /PRNewswire/ -- Cell therapy refers to a treatment that involves the use of living cells to treat diseases. The cell therapy market has been experiencing significant growth due to the rising awareness about the benefits of cell therapies. They help regenerate damaged tissues and organs. They have the potential to treat a range of conditions, such as cancer, autoimmune diseases, infectious diseases, urinary issues, spinal cord injuries, joint cartilage damage, immune system weakness, and neurological disorders. Cell therapies target only damaged tissues, reducing the chances of getting damage to other tissues. Numerous cell types are

    9/18/25 8:45:00 AM ET
    $BMY
    $BNTX
    $CRSP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Computer Software: Programming Data Processing

    Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease

    Definitive agreement to accelerate adoption of Renalytix's FDA-approved, Medicare reimbursed kidneyintelX.dkd test to slow kidney disease progression and improve patient outcomes NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB:RNLXY), today announced an agreement with Tempus AI, Inc. (NASDAQ:TEM) to make kidneyintelX.dkd prognostic blood testing more widely available for eligible patients within its US network of healthcare institutions. Eligible patients have type 2 diabetes with chronic kidney disease, impacting nearly 15 million individuals in the US.

    9/15/25 8:00:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman Lefkofsky Eric P sold $25,457,014 worth of shares (332,500 units at $76.56) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    9/29/25 4:33:00 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Director Epstein David R sold $18,410 worth of Class A Comnmon Stock (250 units at $73.64), decreasing direct ownership by 0.92% to 27,041 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    9/4/25 4:15:07 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Chief Operating Officer Fukushima Ryan sold $758,028 worth of shares (10,000 units at $75.80) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    9/4/25 4:15:11 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    SEC Filings

    View All

    SEC Form 144 filed by Tempus AI Inc.

    144 - Tempus AI, Inc. (0001717115) (Subject)

    9/25/25 7:04:21 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SCHEDULE 13D/A filed by Tempus AI Inc.

    SCHEDULE 13D/A - Tempus AI, Inc. (0001717115) (Filed by)

    9/12/25 4:15:05 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form 8-K filed by Tempus AI Inc.

    8-K - Tempus AI, Inc. (0001717115) (Filer)

    8/27/25 5:11:01 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Tempus AI with a new price target

    H.C. Wainwright initiated coverage of Tempus AI with a rating of Buy and set a new price target of $90.00

    9/2/25 8:40:58 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    BTIG Research initiated coverage on Tempus AI with a new price target

    BTIG Research initiated coverage of Tempus AI with a rating of Buy and set a new price target of $60.00

    4/21/25 8:39:11 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus AI downgraded by Analyst with a new price target

    Analyst downgraded Tempus AI from Overweight to Neutral and set a new price target of $55.00 from $50.00 previously

    2/25/25 7:14:46 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Financials

    Live finance-specific insights

    View All

    Tempus Announces the Acquisition of Paige

    Paige's strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio. Founded in 2017, Paige has developed and deployed several AI applications, including the first FDA-cleared AI application in pathology, allowin

    8/22/25 9:20:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus to Report Second Quarter 2025 Financial Results on August 8

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter of 2025 on Friday, August 8, 2025. The company will hold the earnings conference call at 8:00 a.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7005219 Domestic Dial-in Number: (800) 715-9871 International Dial-in Numbe

    7/22/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Reports First Quarter 2025 Results

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and services Announced multi-year, strategic collaborations with AstraZeneca and Pathos to work together to build the largest multimodal foundation model in oncology, resulting in additional $200.0 million in data licensing and model development fees over the next

    5/6/25 4:01:00 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 5:00:02 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 4:30:28 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13D/A filed by Tempus AI Inc.

    SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)

    8/20/24 4:27:51 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology